https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2026-03-23 16:02:092026-03-23 16:20:37CYGNOS BioTech Awarded U.S. Department of Defense SBIR Phase II Contract
https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2026-01-05 18:03:122026-03-23 16:22:11CYGNOS BioTech, LLC Selected for U.S. Department of Defense SBIR Phase II Negotiation to Advance Broad-Spectrum Antiviral Platform
https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2025-07-08 21:06:392026-03-23 16:08:52CYGNOS BioTech to Present Innovative PVX Antiviral Platform at U.S. DoD and International Scientific Conference
https://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpg00Walid Chaarhttps://cygnosbiotech.com/wp-content/uploads/2023/08/2-300x169.jpgWalid Chaar2025-04-21 15:04:032026-03-23 16:08:39CYGNOS BioTech Awarded Contract to Develop Critical Antiviral Drug Amid New and Emerging Viral Disease Threats
